Payment overview · 2025
General Payments
$351.65
18 reported records · 10 companies
Healthcare provider profile · identity verified
Michael L Miles, MD
Allopathic & Osteopathic Physicians|Family Medicine · DALLAS, GA · NPI 1760458319
Verified facts
What the public records show
CMS Open Payments records show Michael L Miles, MD received $351.65 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.04 | 29.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.40 | 11.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.13 | 11.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.08 | 9.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.45 | 8.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.29 | 8.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.36 | 6.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.56 | 5.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.09 | 4.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.25 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $351.65 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
112 | 95 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
50 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 72 |
| Gabapentin | Gabapentin | 156 | 46 |
| Lisinopril | Lisinopril | 155 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 147 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 28 |
| Jardiance | Empagliflozin | 120 | 34 |
| Metformin Hcl Er | Metformin Hcl | 112 | 36 |
| Ozempic | Semaglutide | 112 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 112 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 31 |
| Tramadol Hcl | Tramadol Hcl | 92 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 33 |
| Metformin Hcl | Metformin Hcl | 86 | 28 |
| Losartan Potassium | Losartan Potassium | 82 | 37 |
| Omeprazole | Omeprazole | 82 | 28 |
| Famotidine | Famotidine | 80 | 29 |
| Ezetimibe | Ezetimibe | 79 | 30 |
| Allopurinol | Allopurinol | 75 | 25 |
| Sertraline Hcl | Sertraline Hcl | 75 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 26 |
| Eliquis | Apixaban | 62 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 26 |
| Mounjaro | Tirzepatide | 59 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 21 |
| Buspirone Hcl | Buspirone Hcl | 56 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 28 |
| Doxepin Hcl | Doxepin Hcl | 53 | 12 |
| Furosemide | Furosemide | 51 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 50 | 50 |
| Glimepiride | Glimepiride | 50 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 13 |
| Trazodone Hcl | Trazodone Hcl | 47 | 13 |
| Potassium Chloride | Potassium Chloride | 44 | 16 |
| Ramipril | Ramipril | 43 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 40 | 40 |
| Alendronate Sodium | Alendronate Sodium | 39 | 11 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Meloxicam | Meloxicam | 36 | 16 |
| Bupropion Xl | Bupropion Hcl | 34 | 11 |
| Carvedilol | Carvedilol | 33 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Clonazepam | Clonazepam | 29 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Prednisone | Prednisone | 28 | 24 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Acetic Acid | Acetic Acid | 17 | 13 |
| Atenolol | Atenolol | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Mupirocin | Mupirocin | 16 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Naproxen | Naproxen | 13 | suppressed |
| Nikki | Ethinyl Estradiol/Drospirenone | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Belsomra | Suvorexant | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $351.65 · 18 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, OTEZLA, PREVNAR 20, REPATHA, REXULTI, SHINGRIX, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error